Wilkinson R, Kapadi A L, Aston E M, Ramsden D B
Acta Endocrinol (Copenh). 1983 Jul;103(3):352-4. doi: 10.1530/acta.0.1030352.
Non-specific beta-blockade with either propranolol or nadolol was shown not to reduce serum TBG concentration in 20 untreated thyrotoxic patients, but to cause significant reductions in the same subjects once they were rendered euthyroid. Similar reductions were also seen in a group of 10 clinically and biochemically euthyroid subjects, who were under investigation for anxiety or mild angina. Since nadolol does not possess the membrane stabilising properties of propranolol, nor is it metabolized like propranolol, the effect on TBG concentration would appear to be due to beta-blockade.
在20例未经治疗的甲状腺毒症患者中,使用普萘洛尔或纳多洛尔进行非特异性β受体阻滞并未显示能降低血清甲状腺素结合球蛋白(TBG)浓度,但在这些患者甲状腺功能恢复正常后,血清TBG浓度显著降低。在一组10例临床和生化检查甲状腺功能正常、因焦虑或轻度心绞痛正在接受检查的受试者中也观察到了类似的降低情况。由于纳多洛尔不具备普萘洛尔的膜稳定特性,其代谢方式也与普萘洛尔不同,因此对TBG浓度的影响似乎是由于β受体阻滞所致。